Impact of the nccn biomarkers compendium on managed care pharmacy

摘要

In December 2012, the National Comprehensive Cancer Network (NCCN) announced the availability of its NCCN Biomarkers Compendium, a new tool developed to support decision making related to biomarker testing in oncology patients.1 Biomarker testing, commonly referred to as molecular testing, is performed to identify specific types of gene expression or mutations that may lead to particular diagnoses or treatment decisions for patients. Often, these tests are undertaken to assess risk, diagnose or classify disease, and/or assess potential response to therapy. By utilizing certain biomarker tests to identify the most appropriate patients for therapy, better patient outcomes may result.